Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial

By sjmartinez • December 17, 2023

Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer. 2023 Dec 16;32(1):34. doi: 10.1007/s00520-023-08176-6. PMID: 38103088; PMCID: PMC10725375.

Tags: breast cancer, Docetaxel /doxorubicin therapy, Efbemalenograstim alfa, Febrile neutropenia, Fusion protein, Granulocyte-colony stimulating factor, Hematology/Oncology, Publications

Understanding Barriers to Colon Cancer Screening Among Individuals Experiencing Housing Insecurity in Los Angeles

Burra A, Gonzales N, Jiang J, Zhang S, Obasi M, Eeraveni A, Garcia Jimenez M, Goldgar S. Understanding Barriers to Colon Cancer Screening Among Individuals[...]

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

Haidar AJ, Chen A, Chen JL, Al-Hashimi S, Ghaffari RS, Fung S, Silverstein J, Konecny GE, Tsui E. Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.[...]

Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease

Riano I, Velez MA, Pomares-Millan H, Blaquier J, Peshin S, Feldman J, Velazquez AI. Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion[...]